| Objectives To observe the effect of Xuezhikang combined with Ezeimibe on stable coronary artery disease(phlegm-blood stasis syndrome)with statin intolerance and the effects of serum lipids,hs-CRP,Hcy,ALT,AST and the security.Methods A total of 70 patients of stable coronary artery disease(phlegm-blood stasis syndrome)with statin intolerance from Cangzhou hospital of integrated TCM-WM · Hebei divided into an experimental group(35 cases)and a control group(35 cases).In the control group,conventional treatment was used,and Ezetimibe 10 mg qd was selected as lipidlowering drug?In the experimental group,the 0.6g bid of Xuezhikang capsule was added on the basis of the control group.the observation course of treatment was 60 days.The TCM syndrome score,CCS grading of angina pectoris,nitroglycerin dosage,ECG,blood lipid,hs-CRP,Hcy,ALT,AST and other indicators collected before and after the test were analyzed to evaluate the efficacy and safety of the drug.Statistical analysis was performed using SPSS 22.0 statistical software.P<0.05 was considered as statistically significant.Results In this study,a total of 70 patients were included,1 case of the control group was shed,and a total of 34 cases were completed.In the test group,2 cases were eliminated,1 case was removed,and a total of 32 cases were completed.The data of 66 cases were analyzed.There was no difference in gender,age and course of disease between the two groups before the treatment.1)TCM syndrome scores: Compared with before the treatment,the TCM syndrome scores in both groups decreased after the treatment,which was statistically significant(P<0.05).Compared among the groups,the experimental group decreased significantly with statistical significance(P<0.05).2)Efficacy of angina pectoris: the effective rates of the control group and the experimental group were 58.82% and 84.36%,respectively.The effective rates of the experimental group were higher than those of the control group with statistical significance(P<0.05).3)Nitroglycerin consumption: Compared with before the treatment,the dosage of drugs in both groups decreased after the treatment,which was statistically significant(P<0.05).However,the stopping rates of nitroglycerin in the control group and the experimental group was 50.00% and 68.75%,respectively,and the comparison between the two groups was not statistically significant(P>0.05).4)ECG: The effective rates of the control group and the experimental group were 61.76% and 81.25%,respectively.There was no statistical significance in the comparison between the two groups(P>0.05).5)The biochemical indicators: Compared with before the treatment,TC,TG,LDL-C,hs-CRP,Hcy,ALT and AST in the two groups all decreased after the treatment,and HDL-C increased,which was statistically significant(P<0.05).Compared with the control group,TC,TG,LDL-C,hs-CRP,Hcy,ALT and AST in the experimental group were significantly decreased,which was statistically significant(P<0.05).Compared with the control group,HDL-C in the experimental group was significantly increased,which was statistically significant(P<0.05).6)Safety: Compared with before the treatment,the Urea and Cr in both groups have no significant change after the treatment,which was no statistically significant(P<0.05).No allergy and other adverse reactions.The drugs have good safety profile.Conclusions 1 Xuezhikang combined with Ezetimibe and Ezetimibe alone can regulate blood lipid level in patients with statin intolerance stable coronary heart disease(phlegmstasis syndrome),improve vascular inflammation and endothelial cell function,treat liver enzyme increase caused by statin intolerance and improve angina pectoris and accompanying symptoms.the former is more effective.2 Xuzhikang combined with Ezeimibe and Ezeimibe alone could improve the ECG and reduce the amount of nitroglycerin.The two are equally effective.3 The two treatments have no significant effect on renal function and no allergic reaction.Both groups have good safety.Figure0;Table16;Reference 146... |
PDF Full Text Request